334 related articles for article (PubMed ID: 31823522)
21. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
Wang C; Zhang W; Fu M; Yang A; Huang H; Xie J
Oncol Rep; 2015 Jan; 33(1):383-90. PubMed ID: 25394408
[TBL] [Abstract][Full Text] [Related]
22. [A novel chemo-resistant gene MSX2 discovered by establishment of two pancreatic cancer drug resistant cell lines JF305/CDDP and PANC-1/GEM].
Yuan W; Sui CG; Ma X; Ma J
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):330-334. PubMed ID: 29860758
[No Abstract] [Full Text] [Related]
23. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
24. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
[TBL] [Abstract][Full Text] [Related]
25. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
27. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
28. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
30. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
32. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
33. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis.
Mao X; Xu J; Xiao M; Liang C; Hua J; Liu J; Wang W; Yu X; Meng Q; Shi S
Redox Biol; 2024 Jul; 73():103200. PubMed ID: 38781729
[TBL] [Abstract][Full Text] [Related]
34. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
[TBL] [Abstract][Full Text] [Related]
35. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
37. Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells.
Xu C; Yu Y; Ding F
Oncol Rep; 2018 Jul; 40(1):395-404. PubMed ID: 29781033
[TBL] [Abstract][Full Text] [Related]
38. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
[TBL] [Abstract][Full Text] [Related]
39. Nicotine promotes epithelial to mesenchymal transition and gemcitabine resistance via hENT1/RRM1 signalling in pancreatic cancer and chemosensitizing effects of Embelin-a naturally occurring benzoquinone.
Prashanth N ; Meghana P ; Sandeep Kumar Jain R ; Pooja S Rajaput ; Satyanarayan N D ; Raja Naika H ; Kumaraswamy H M
Sci Total Environ; 2024 Mar; 914():169727. PubMed ID: 38163613
[TBL] [Abstract][Full Text] [Related]
40. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]